Brenmiller Energy Launches BNRG360 Clean Energy Solutions
Brenmiller Energy announced BNRG360, a new integrated strategy under which the Company will offer industrial customers comprehensive clean energy solutions covering both heat and electricity. BNRG360 represents a strategic evolution of the Company's business model, expanding beyond technology supply to the delivery of integrated energy services. Leveraging on its experience in renewable projects, Brenmiller will combine its bGen TES systems with solar PV and battery energy storage, enabling customers to procure decarbonized heat and power under long-term contractual arrangements. Through BNRG360, industrial clients will be able to access Heat-as-a-Service and Power Purchase Agreement structures, without upfront capital expenditure, reducing project risk."The launch of BNRG360 reflects a clear evolution in how we create value," said Avi Brenmiller, CEO. "Industrial customers are increasingly looking for a single, accountable party to manage their energy requirements. By integrating power generation, storage and thermal assets, we enable customers to outsource the complexity of their energy systems to an expert provider, while securing reliable, cost-effective heat and electricity and allowing them to focus on their core business."
Discover Tomorrow's Bullish Stocks Today
Analyst Views on BNRG
About BNRG
About the author
Brenmiller Energy (BNRG) to Implement 7-for-1 Reverse Split on January 23, 2026
- Reverse Split Announcement: Brenmiller Energy has announced a 7-for-1 reverse split effective after market close on January 23, 2026, reducing its outstanding shares from approximately 5.01 million to about 716,000, which aims to increase the share price and attract more investor interest.
- Shareholder Approval: The reverse split plan was approved by shareholders on January 13, reflecting confidence in the company's future and providing support for its continued listing on the Nasdaq Capital Market.
- Trading Schedule: The company's shares are expected to begin trading on a post-split basis on January 26, 2026, under the same ticker symbol BNRG, ensuring convenience for investors during the transition.
- Authorized Capital Unchanged: Despite the significant reduction in outstanding shares, the company's authorized share capital will remain unchanged, indicating that Brenmiller retains the capacity for future financing or equity adjustments to support its business growth.
Vanda Pharmaceuticals' NEREUS Receives FDA Approval, Shares Surge 17.5%
- FDA Approval: Vanda Pharmaceuticals' NEREUS (tradipitant) has received FDA approval for the prevention of motion-induced vomiting in adults, marking a significant advancement in the company's neuropharmaceutical portfolio and is expected to drive future sales growth.
- Stock Surge: Following the FDA approval announcement, Vanda's shares jumped 17.5% to $8.26 in pre-market trading, reflecting strong market confidence in the new drug's potential and likely attracting increased investor interest.
- Market Outlook: The approval of NEREUS not only opens new market opportunities for Vanda Pharmaceuticals but also enhances its market share in the competitive antiemetic drug sector, strengthening the company's long-term profitability prospects.
- Investor Confidence: This FDA approval boosts investor expectations for Vanda's future performance, potentially prompting more institutional investors to reassess their portfolios, further driving the stock price upward.
